Pipeline


Esperance is developing novel, targeted oncology product candidates that selectively kill cancer cells without harming normal cells. The cationic lytic peptide (CLYPTM) technolgy platform is delivering multiple membrane distupting peptides (MDPs) and antibody drug conjugates (ADCs).

 

Product Candidate

Target

Potential Indications

Status

EP-100

Peptide conjugate



LHRH-Receptor

Solid tumors (ovarian, breast, endometrial, prostate, pancreatic) and blood cancers

Phase 2

       

EP-200

Peptide conjugate



LH/hCG-Receptor



Solid tumors (breast, prostate, endometrial, ovarian)

Proof of concept demonstrated in vitro and in vivo

       

EP-300

Peptide conjugates



FSH-Receptor

(anti-angiogenesis)



Solid tumors and blood cancers

Proof of concept demonstrated in vitro and in vivo

       

Antibody drug conjugates (ADCs)

HER2 and CD20



Solid tumors (breast, gastric, bladder) and blood cancers

Production in bacteria, yeast and mammalian cells; in vitro activity demonstrated